Monitoring and ajustment of immunosuppression after the heart transplantation;Suivi du patient après transplantation cardiaque: Monitoring et adaptation de l'immunosuppression

Revue Medicale Suisse

Volumn 5, Issue 205, 2009, Pages 1214-1220

  Yerly, Patrick ^a   Mach, François ^c   Kalangos, Afksendiyos ^d   Rotman, Samuel ^b   Von Segesser, Ludwig ^a   Vogt, P ^e   Hullin, Roger ^a   Pascual, Manuel ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

^c Service de Cardiologie   (Switzerland)

^d HUG   (Switzerland)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PREDNISONE; RAPAMYCIN; STEROID;

DRUG MECHANISM; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; REVIEW; SURVIVAL;

CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; CYCLOSPORINE; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; GRAFT REJECTION; GRAFT SURVIVAL; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; META-ANALYSIS AS TOPIC; MONITORING, IMMUNOLOGIC; MYCOPHENOLIC ACID; PROTEIN KINASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TACROLIMUS; TREATMENT OUTCOME;

EID: 67549144094     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Taylor DO, Edwards LB, Aurora P, et al. Registry of the International society for heart and lung transplantation: 25th official adult heart transplant report - 2008. J Heart Lung Transplant 2008;27:943-956 (Pubitemid 36773674)
2. ** Hunt SA, Haddad F. The changing face of heart transplantation. JACC 2008;52:587-598
3. Moll S, Pascual M. Humoral rejection of organ allografts. Am J Transplant 2005;5:2611-2618 (Pubitemid 43920053)
4. Halloran PF. Immunosuppresive drugs for kidney transplantation. N Engl J Med 2004;351:2715-2729
5. * Mueller XM. Drug immunosuppression therapy for adult heart transplantation. Part 2: Clinical applications and results. Ann Thorac Surg 2004;77:363-371
6. Uber PA, Mehra MR. Induction therapy in heart transplantation: Is there a role? J Heart Lung Transplant 2007;26:205-209
7. * Zuckermann AO, Aliabadi AZ. Calcineurin-inhibitor minimization protocols in heart transplantation. Transplant International 2009;22:78-89.
8. Carrier M, White M, Perrault LP, et al. A 10-year experience with intravenous thymoglobulin in induction of immunosuppression following heart transplantation. J Heart Lung Transplant 1999;18:1218-1223
9. Kobashigawa J, Mehra M, West L, et al. Report from a Consensus conference on the sensitized patient awaiting heart transplantation. J Heart Lung Transplant 2009;28:213-225
10. Patel JK, Kobashigawa JA. Cardiac transplant experience with cyclosporine. Transplant Proc 2004;36:323S-30. (Pubitemid 38373886)
11. Opelz G. Multicenter evaluation of immunosuppressive regimen in heart transplantation. The Collaborative transplant study. Transplant Proc 1997;29:617. (Pubitemid 27123553)
12. Greenberg A, Egel JW, Thompson ME, et al. Early and late forms of cyclosporine nephrotoxicity: Studies in cardiac transplant recipients. Am J Kidney Dis 1987;9:12-22. (Pubitemid 17039814)
13. Kobashigawa J, Miller L, Russel S, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1 year report. Am J Transplant 2006;6:1377-1386 (Pubitemid 44030320)
14. Grimm M, Rinaldi M, Yonan N, et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients - a large European trial. Am J Transplant 2006;6:1387-1397 (Pubitemid 44030321)
15. Ye F, Ying-Bin X, Yu-Guo W, Hetzer R. Tacrolimus versus cyclosporine microemulsion for heart transplant recipients: A meta-analysis. J Heart lung Transplant 2009;28:58-66.
16. Kobashigawa JA, Starling RC, Mehra MR, et al. Multicenter retrospective analysis of cardiovascular risk factors affecting long-term outcome of de novo cardiac transplant recipients. J Heart Lung transplant 2006;25:1063-1069 (Pubitemid 44311519)
17. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998;66:507-515 (Pubitemid 28415379)
18. Manuel O, Venetz JP, Fellay J, et al. Efficacy and safety of universal valganciclovir prophylaxis combined with a tacrolimus/mycophenolate-based regimen in kidney transplantation. Swiss Med Wkly 2007;137:669-676 (Pubitemid 350221801)
19. Legendre C, Pascual M. Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: Late-onset disease and indirect consequences. Clin Infect Dis 2008;46:732-740 (Pubitemid 351321558)
20. Hamour IM, Lyster HS, Burke MM, Rose ML, Banner NR. Mycophenolate mofetil may allow cyclosporine and steroid sparing in de novo heart transplant patients. Transplantation 2007;83:570.
21. Chan L, Mulgaonkar S, Walker R, et al. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 2006;81:1290-1297 (Pubitemid 43804549)
22. Kaczmarek I, Ertl B, Schmauss D, et al. Preventing cardiac allograft vasculopathy: Long-term beneficial effects of mycophenolate Mofetil. J Heart Lung Transplant 2006;25:550-556
23. Keogh A, MacDonald P, Mundy J, et al. Five-year follow-up of a randomized double-drug vesrsus triple-drug thrapy immunosuppressive trial after heart transplantation. J Heart Lung Transplant 1992;11:550-556
24. Oaks TE, Wannenberg T, Close SA, Tuttle L, Kon N. Steroid free maintenance immunosuppression after heart transplantation. Ann Thorac Surg 2001;72:102-106 (Pubitemid 32643017)
25. Eisen HJ, Tuzcu EM, Dorent R, et al. RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003;349:847-858 (Pubitemid 37025404)
26. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: A randomized clinical trial. Circulation 2004;110:2694-2700 (Pubitemid 39453021)
27. Zuckermann A, Manito N, Epailly E, et al. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J Heart Lung Transplant 2008;27:141-149 (Pubitemid 351221042)
28. Lehmkuhl, HB, Mai D, Dandel M, et al. Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients. J Heart Lung Transplant 2007;26:700-704 (Pubitemid 47007710)
29. Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003;108:48-53. (Pubitemid 36859019)
30. Hunt J, Bedanova H, Starling RC, et al. Premature termination of a prospective, open-label, randomized, multicenter of SRL to replace CNIs in a standard care regimen CNI, MMF and corticosteroids early after heart transplantation. J Heart Lung Transplant 2007;26(Suppl. 2):S203.
31. Raichlin E, Khalpey Z, Kremers W, et al. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients. Transplantation 2007;84:467-474 (Pubitemid 47312156)
32. Deng MC, Eisen HJ, Mehra MR, et al. Non-invasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 2006;6:150-160 (Pubitemid 43382213)
33. Codarri L, Valloton L, Ciuffreda D, et al. Expansion and tissue infiltration of an allospecific CD4+ CD25+ CD45RO+ IL-7alphahigh celle population in solid organ transplant recipients. J Exp Med 2007;204:1533-1541
34. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005;24:1710.